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Enabling access to new WHO essential medicines:







Nicotine replacement therapies (NRT) are powerful tools for the successful treatment of nicotine addiction and
tobacco use. The medicines are clinically effective, supported by the Framework Convention on Tobacco Control,
and are now World Health Organization-approved essential medicines. Enabling global access to NRT remains a
challenge given ongoing confusion and misperceptions about their efficacy, cost-effectiveness, and availability with
respect to other tobacco control and public health opportunities. In this commentary, we review existing evidence
and guidelines to make the case for global access to NRT highlighting the smoker’s right to access treatment to
sensibly address nicotine addiction.
Tobacco use kills 5.4 million people annually. Even if no
children started smoking in the future, 8.3 million peo-
ple will die annually of tobacco-related diseases by 2030.
Unless tobacco cessation and control vastly improves,
the death toll from tobacco this century will easily reach
an estimated 1 billion deaths [1]. In this paper, we dis-
cuss the benefits and challenges of enabling access to
pharmacotherapies [nicotine replacement therapies
(NRTs)] to treat nicotine dependence and bolster
tobacco cessation in low and middle income countries
(LMIC).
In March 2009, NRTs (specifically, nicotine gums and
patches) were added to the Model List of Essential Med-
icines by the World Health Organization (WHO) [2].
Essential medicines are defined as those that satisfy the
priority health care needs of the population, and the
Essential Medicines List (EML) is used by over 160 gov-
ernments as a guide for determining which medicines
should be made available to their citizens at low cost
(http://www.who.int/medicines/en/ and Figure 1). The
addition of a medicine to the international EML directly
encourages individual nations to add the drug to their
national EML and to internal drug registries. This is an
important logistical step. Many countries (e.g. South
Africa) restrict drug importations to medicines on
national EML and registries. Similarly, several
foundations and major charities base their medicine
supply on the WHO EML. Medicines not on the inter-
national or national EML are often not available or are
simply unaffordable in LMIC.
In this context, we argue that in light of the increasing
global burden of tobacco dependence and the clinical
utility of NRT, these new WHO essential medicines can
and should be available more widely. Let us be clear at
the outset. We do not argue that every smoker in a
given population should use NRT to quit. Rather, we
posit that a nicotine-dependent individual in a low
resource country should have the opportunity to afford-
ably access the medicines to treat his or her tobacco
dependence.
Clinical Cessation with NRT: The Evidence
Tobacco dependence treatment “includes (singly or in
combination) behavioral and pharmacological interven-
tions such as brief advice and counseling, intensive sup-
port, and administration of pharmaceuticals, that
contribute to reducing or overcoming tobacco depen-
dence in individuals and in the population as a whole
[3].” In this commentary, we focus specifically on access
to NRT, one aspect of tobacco dependence treatment.
NRT represent a specific class of nicotine-delivering
pharmaceuticals that help people stop smoking by curb-
ing nicotine withdrawal symptoms.
T h em o s tr e c e n tC o c h r a n er e v i e wf r o m2 0 0 8 ,u s i n g
pooled data from over 40,000 people in 111 trials
between 1979-2007, shows that the relative risk of
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more was 1.58 compared with controls (95% Confidence
Interval (CI): 1.50-1.66) [4]. According to the 2008 US
Public Health Service (USPHS) guidelines, the number
of smokers needed to be treated with NRT to achieve
o n eq u i tr a n g e df r o m8f o rl o n gt e r mu s eo f( >1 4
weeks) nicotine gum to 10 for nicotine patch and 20 for
short term use of nicotine gum [3]. The estimated abso-
lute 6-month smoking abstinence rates for NRT patch
and long term gum were 23.4% and 26.1%, respectively,
compared to 13.8% for placebo [3]. Given the efficacy
and relatively low cost of NRT, the addition of NRT to
the EML represents an important potential milestone
for furthering the goals of global tobacco control while
moving towards equitable access to essential medicines.
NRT and brief counseling (in the clinical setting or
through telephone quitlines) represent effective and
inexpensive clinical treatment approaches for helping
the large number of individuals dependent on nicotine
worldwide to quit using tobacco. Group and individual
counseling increases significantly the odds of successful
quitting by a factor of 1.3-1.7 above baseline [3]. The
combination of counseling with medications works to
synergistically increase quit rates by a factor of 1.7 over
counseling alone [3]. We argue that in concert with
effective societal approaches to reduce tobacco use
through higher tobacco taxes and social denormalization
of tobacco use ("unassisted cessation”), clinical treatment
options such as counseling and NRT should be available
to help those that cannot quit without support. To only
promote unassisted cessation without making available
NRT to those who cannot or will not quit on their own
denies the known addictive nature of nicotine, as well as
the known harm of exposing nicotine addicts to stigma-
tizing policies and economic burdens without the option
to help them quit.
By present international standards, NRT can be con-
sidered a cost-effective clinical intervention-one estimate
predicted that achievement of 25% global coverage with
NRT would cost US$ 276-279 per disability-adjusted life
year averted in East Asia [5]. In a low-income country,
the cost of cessation therapy with short-term use of
NRT (e.g. 8 weeks of patches) is US $50 [5]. Prices of
NRT, while still relatively high in the developing world,
m a yb ef a l l i n g .I nI n d i a ,t h ep r i c eo fN R Ta so f2 0 0 3
was approximated at $0.65 per day for a three month
course in 2003 - still high, but 12% of that in the United
States [5]. In the widely respected Disease Control Prio-
rities Project published in 2006, Prabhat Jha and collea-
gues estimated that providing NRT with an effectiveness
of even 1% above baseline in low and middle countries
could save nearly 3 million lives over the next half cen-
tury; if the effectiveness is 5%, they estimated that over
14 million lives would be saved [6]. These estimates
translate into a reasonable range of cost effectiveness in
low and middle income countries; comparable to other
proven public health strategies (See Figure 2).
Perhaps the most convincing evidence comes from the
real-word distribution campaigns of NRT. In 2003, the
New York City Department of Health and Mental
Hygiene, leaders in instituting public smoking bans,
began a widely publicized campaign to distribute free
NRT [7]. In total, they estimated that they sent nicotine
patches to roughly 5% of the total adult smoking popu-
lation in New York City during the short campaign [7].
All of the smokers smoked at least 10 cigarettes daily
and 60% of the smokers were non-white, foreign born
or from low-income neighborhoods. When checked 6
months later, more NRT recipients than the control
group members successfully quit smoking (33% vs 6%,
p = 0.0001); with over 6000 successful quits, this pro-
gram yielded a cost of $464 per quit [7].
Recent data specific to LMICs suggest that the medi-
cines would be as efficacious as they are in developed
countries, provided the delivery infrastructure is present.
These include a study of 341 patients in Brazil that
showed greater than 25% 12-month cessation rate for
those receiving counseling and NRT vs. 14.5% for coun-
seling alone [8], along with other studies in Hong Kong
[9] and Venezuela [10] showing similar efficacy. How-
ever, the effectiveness of NRT in the real-world in
LMICs remains untested.
Figure 1 The concept of essential medicines.
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In light of the tremendous toll of tobacco use, the
world’s first global public health treaty, the Framework
Convention on Tobacco Control (FCTC), was developed
and first signed in 2003 by WHO member states http://
www.who.int/fctc/en/. The FCTC emphasizes both a
reduction in the demand and supply of tobacco through
the implementation of the MPOWER package of poli-
cies [1]. These policies include Monitoring tobacco use,
Protecting people from secondhand smoke, Offering
treatment for tobacco dependence, Warning people of
the dangers of tobacco use, Enforcing advertising bans,
and Raising tobacco taxes [1].
To date, however, the majority of global efforts have
focused on all the items of the MPOWER package
except offering treatment. Some have even remarked,
only in half-jest, that the “O” stands for “orphan,” not
offer treatment. However, Article 14 of the FCTC clearly
requires the 169 signatory nations:
“to develop and disseminate appropriate, compre-
hensive and integrated guidelines based on scientific
evidence and best practices, taking into account
national circumstances and priorities...and take effec-
tive measures to promote cessation of tobacco use
and adequate treatment for tobacco dependence...
[and] to collaborate with other parties to facilitate
accessibility and affordability for treatment of
tobacco dependence including pharmaceutical
products...”[11].
Progress on implementing the FCTC protocols
remains mixed. In 2008, comprehensive treatment ser-
vices to help users overcome tobacco dependence were
available in only 17 countries representing 8% of the
world’s population; none of these countries were in the
developing world [12]. At the 14th World Conference
on Tobacco or Health in Mumbai, India in March 2009,
the convened body recommended that by 2012, the
majority of parties to the FCTC should begin to provide
national tobacco cessation efforts as recommended
under Article 14.
While the FCTC is catalyzing some tobacco control
success worldwide, the tobacco industry continues to
market aggressively and successfully. Smoking preva-
lence remains close to 25% in the 30 high- and middle-
income countries belonging to the Organisation for
Figure 2 Cost-effectiveness (Cost (USD) per DALY averted) of selected health priorities in LMICs, 2006 (adapted from [28].
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increasing in LMIC, especially among women. Currently,
in Matlab, Bangladesh, nearly 70% of men and 33% of
women smoke or use smokeless tobacco [13]. The effect
of these practices is striking with 79% of deaths in
Matlab attributed at present to non-communicable dis-
eases, many of which are linked to the use of tobacco
[14]. Male Bangladeshi smokers currently spend twice as
much on tobacco as on education, health, and other
household expenditures combined [15]. To this end, the
inclusion of NRT on the EML may help catalyze the
inclusion of tobacco treatment into clinical systems
across the developing world.
Challenges & Counter-arguments
Alternative Cessation Methods
Are we in danger of over-hyping NRT for use in devel-
oping countries or “over-medicalizing” the treatment of
tobacco use? We acknowledge that these medicines are
not a panacea, and that most evidence for their efficacy
comes from the developed world. NRT and behavioral
programs typically help fewer than 30% of smokers who
use them to quit over the long-term. Cultural norms
around tobacco use and cessation, as well as knowledge
about the harms of tobacco, are different in LMIC com-
pared to developed countries. Investment in upstream
approaches to modify the social climate around tobacco
use, bans on advertising and promotion, and clean
indoor air laws are important first approaches in
resource-scarce public health environments[16]. While
there is some controversy around the population-wide
or “real-world” effect of NRT in developed countries
[17,18], new evidence from Massachusetts suggests a
likely association between increased insurance coverage
for, and use of, smoking cessation medications with
increased quit attempts and decreased smoking preva-
lence among low-income smokers on public insurance
[19]. Furthermore, Grassi et al (2009) showed that con-
comitant clean indoor air laws can synergistically
increase rates of successful cessation among smokers
treated for tobacco use in a clinical setting[20].
What is clear, regardless of one’s point of view on the
best method of cessation, is that nicotine-dependent
patients deserve the right to affordable access for these
treatments if they so choose. This is especially true consid-
ering the cost-effectiveness of NRT compared to many
other widely used clinical interventions (See Figure 2). For
example, combination use of statins and anti-hypertensives,
all WHO essential medicines [2,21] used for the control of
cardiovascular disease is much less cost-effective than
NRT. Further, the use of directly observed chemotherapy
for tuberculosis or tobacco advertising bans feature com-
parable cost-effectiveness to NRT use - estimates that hold
up in both developed and developing world settings.
To this end, the newly acquired WHO essential medi-
cine status can and should encourage WHO member
states in low and middle income regions to register
NRT for use in their countries. While more evidence is
needed to understand quit rates using NRT in LMICs as
well as optimal ways to provide treatment services
within resource-poor settings, there is no prima facie
reason to believe that NRT is not effective in the devel-
oping world (reviewed below). In fact, the EML commit-
tee did not demand confirmatory proof of effectiveness
in the developing world before including other medica-
t i o n ss u c ha sp r o t o np u m pi n h i b i t o r sa n do n c o l o g i c
chemotherapeutics in the EML.
Just how NRT use is best parceled out within the lar-
ger tobacco treatment clinical context in low resource
settings remains an open question deserving of further
rigorous empirical study. To be sure, the preventive and
treatment approaches need not be viewed as mutually
exclusive, even in resource-starved environments. The
approaches can complement one another [20] and
smoking cessation services are most effective in the con-
text of coordinated tobacco control [12].
Role of the Pharmaceutical Industry
In a field sensitive to conflict of interest and accustomed
to dealing with now infamous tactics of tobacco industry
deceit [22] there is some understandable skepticism of
the role of pharmacotherapy in cessation [23], particu-
larly regarding the reliability of industry-backed trials or
excessive hype over these medicines. This skepticism,
however, does not change the fact that the drugs have
been shown to work empirically and, based on this evi-
dence, have been incorporated into major national and
international health platforms (including the FCTC and
EML). The large scale distribution of free NRT by large
urban public health agencies underscores this trend [7].
If anything, the essential medicine status of NRT
should now help break down structural and price bar-
riers maintained by the pharmaceutical industry that
prohibit patients, particularly in lower income countries,
from accessing these medicines in an affordable manner
(such as being sold in single use quantities). Targeted
expansion of generic production of these medicines,
including the use of humanitarian licensing and
enhanced drug donation schemes to augment NRT
availability and drive costs down, are needed urgently
f o rt h e s ec e s s a t i o np r o g r a m st ow o r ki nc o n c e r tw i t h
other public tobacco control strategies.
Uptake and Delivery of NRT in LMIC
It is unclear whether the packaging and delivery of a phar-
macotherapy is tenable currently for many smokers in
LMIC. There is little to no cultural awareness of how
these medicinal products could help in cessation, particu-
larly in an environment where cessation is not normative.
In fact, the use of NRT has been largely untested in LMIC
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vices, as levered by the HIV/AIDS and Tuberculosis (TB)
treatment communities, as well as deregulation of the
medicines for over-the-counter treatment can help, but
require further detailed study in LMIC for NRT. Cessation
efforts should be naturally integrated into ongoing efforts
to strengthen primary care. Critically, the process of work-
ing with existing treatment providers in LMIC to identity
target populations (such as patients with TB) to offer
effective counseling and deliver NRT to a larger group of
tobacco users worldwide is a necessary step to reduce
tobacco use [5,24].
Financing
A final thorny issue, currently unanswered, is who will
actually pay for the treatments? Is it the role of the indi-
vidual patient or of the government or even of large
pharmaceutical companies distributing these medica-
tions for free or at reduced prices? Lists of essential
medicines guide the procurement and supply of medi-
cines in the public sector, with several LMIC with social
health insurance programss u b s i d i z i n gc o v e r a g eo f
EML-listed medicines. The use of government tax on
tobacco revenues could help finance telephone quit lines
and clinical cessation services, including distribution of
NRT to nicotine dependent patients [9].
It is clear that governments need to prioritize their
funding of drugs on the EML proportional to the
expected public health gains. Further, WHO and gov-
ernments must negotiate with NRT manufacturers to
ensure that NRTs are affordable in key LMIC markets.
Given the growing burden of tobacco, even low-income
countries (e.g. Bangladesh) may find ways to prioritize
multimodal tobacco control strategies. These strategies,
including cessation treatment, can naturally synchronize
with a growing political, social and technical movement
to drive resources to control non-communicable chronic
diseases (NCDs) and their risk factors (particularly
tobacco) through a planned United Nations high-level
meeting on NCDs in September 2011 [25-27].
As outlined in the most recent WHO MPOWER
report on global tobacco, “in the vast majority of low-
and middle-income countries, the cost of cessation
assistanceis not covered by the government, and 8% of
middle income and 29% of low-incomecountries provide
no assistance at all.” [9] Hence, it is imperative for
countries to make the medicines available and more
affordable (through drug registration and direct import)
to individual nicotine-dependent patients who want
them at pharmacies in both urban and rural locales.
Further, it is reasonable for countries to consider
stocking NRT for use in ambulatory clinical settings
among particularly high-risk tobacco users such as
newly diagnosed TB patients or patients with severe
chronic obstructive pulmonary disease. Whether a
population-based effort to promote more widespread
NRT use would be clinically appropriate or economic-
ally feasible in the near future remains an open question
in need of more study.
Concluding thoughts
Though a vital part of tobacco control, clinical tobacco
treatment is often neglected. It is now clear that neither
public health interventions like smoking bans or
increased taxes, nor clinical strategies like offering NRT,
are sufficient alone. Lasting progress toward reducing the
burden of tobacco will only be made by integrating these
crucial legislative, financial, and clinical approaches.
Coupled with the FCTC and heightened political atten-
tion on NCDs and tobacco control, NRT provides
another valuable tool for reducing the global burden of
tobacco use. It is now more important than ever that
countries swiftly register these medicines, and liaise with
appropriate generic manufacturers to augment availabil-
ity and harmonize clinical cessation into systems-level
clinical care. The real question now is when will we act?
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